John P. Hamill
2023 - Aprea Therapeutics
In 2023, John P. Hamill earned a total compensation of $908.4K as Chief Financial Officer at Aprea Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $189,340 |
|---|---|
| Option Awards | $197,275 |
| Salary | $387,917 |
| Stock Awards | $133,851 |
| Total | $908,383 |
Hamill received $387.9K in salary, accounting for 43% of the total pay in 2023.
Hamill also received $189.3K in non-equity incentive plan, $197.3K in option awards and $133.9K in stock awards.
Rankings
In 2023, John P. Hamill's compensation ranked 1,302nd out of 2,918 executives tracked by ExecPay. In other words, Hamill earned more than 55.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,302 out of 2,918 | 55th |
Division Manufacturing | 785 out of 1,608 | 51st |
Major group Chemicals And Allied Products | 520 out of 901 | 42nd |
Industry group Drugs | 507 out of 864 | 41st |
Industry Pharmaceutical Preparations | 352 out of 622 | 43rd |
Source: SEC filing on April 25, 2024.
Hamill's colleagues
We found two more compensation records of executives who worked with John P. Hamill at Aprea Therapeutics in 2023.
News
Aprea Therapeutics CFO John Hamill's 2023 pay jumps 62% to $908K
April 25, 2024
Discovery Laboratories CEO Craig Fraser's 2022 pay falls 50% to $941K
June 29, 2023
Discovery Laboratories CEO Craig Fraser's 2021 pay jumps 144% to $1.9M
May 11, 2022
Discovery Laboratories COO Eric Curtis receives $1.8M in 2020
April 30, 2021
Cellectar Biosciences CEO James Caruso's 2018 pay falls 23% to $770K
April 29, 2019